Patents by Inventor Ivo Lorenz
Ivo Lorenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124581Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: ApplicationFiled: September 1, 2023Publication date: April 18, 2024Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAAF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, Jr., Haiguang XIAO, Danlin YANG
-
Publication number: 20240115721Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Publication number: 20240115720Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Patent number: 11891416Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: October 19, 2020Date of Patent: February 6, 2024Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.Inventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
-
Publication number: 20240000959Abstract: The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.Type: ApplicationFiled: November 30, 2021Publication date: January 4, 2024Inventors: Neil H. BANDER, Wilhem LECONET, Ming GUO, He LIU, Ivo LORENZ, Abdul G. KHAN
-
Publication number: 20230391890Abstract: The present disclosure relates to antibody-based molecules, including antibodies, epitope-binding domains thereof, and antibody derivative as described herein, that are capable of binding and inhibiting cell migration-inducing and hyaluronan-binding protein (CEMIP). Such antibody-based molecules are useful for the treatment of conditions where a subject is in need of blocking the activity of CEMIP.Type: ApplicationFiled: October 15, 2021Publication date: December 7, 2023Inventors: David C. LYDEN, Goncalo RODRIGUES, Irena RAJNPREHT, Abdul KHAN, Ivo LORENZ, Irina MATEI
-
Patent number: 11795219Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 11, 2020Date of Patent: October 24, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
-
Publication number: 20230190797Abstract: Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.Type: ApplicationFiled: July 2, 2018Publication date: June 22, 2023Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David A. SCHEINBERG, Thomas J. GARDNER, Derek S. TAN, Jonghan LEE, Ivo LORENZ
-
Publication number: 20220348648Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.Type: ApplicationFiled: July 8, 2020Publication date: November 3, 2022Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ
-
Publication number: 20220220222Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.Type: ApplicationFiled: December 23, 2021Publication date: July 14, 2022Applicant: Inspirna, Inc.Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
-
Publication number: 20220153863Abstract: The present invention provides various PRAME binding molecules (including antibodies, antibody fragments, chimeric antigen receptors, and the like), compositions and cells (including T cells) comprising such PRAME binding molecules, and methods of using such PRAME binding molecules, compositions and cells, for example in the detection and/or monitoring of PRAME-positive tumors.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Inventors: Hans David Staffan Ulmert, Richard John O'Reilly, Ivo Lorenz, Mary Ann Pohl, Namita Trikannad
-
Patent number: 11242407Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.Type: GrantFiled: February 25, 2020Date of Patent: February 8, 2022Assignee: Inspirna, Inc.Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
-
Publication number: 20210380696Abstract: The present invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.Type: ApplicationFiled: May 24, 2021Publication date: December 9, 2021Inventors: David A. BLAIR, Nicole K. GARAFFA, Pankaj GUPTA, Priyanka GUPTA, Fei HAN, Aaron Timothy KARLAK, Dongmei LIU, Ivo LORENZ, Mouhamadou Lamine MBOW, Miguel E. MORENO-GARCIA, Joseph A. MOZDZIERZ, Kerry L.M. RALPH, Abdulsalam SHAABAN, Della M. WHITE, Helen Haixia WU, Guangwei YANG
-
Patent number: 11028169Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 18, 2017Date of Patent: June 8, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
-
Patent number: 11008989Abstract: Various embodiments include a fuel rail assembly for an internal combustion engine comprising: an elongate, common fuel rail having a reservoir for a fuel supply; a plurality of adapters spaced along and fixed to a wall of the fuel rail for hydraulically connecting a respective fuel injector to the reservoir in the common rail; and a respective fuel passage associated with each adapter of the plurality of adapters, each fuel passage directing fuel from the reservoir to the associated adapter. Each fuel passage comprises an inlet end open to the reservoir and an upstream end section adjacent to the inlet end having a length and a cross-sectional area forming a smoothing function to smooth pressure fluctuations in the fuel entering the respective passage.Type: GrantFiled: September 28, 2017Date of Patent: May 18, 2021Assignee: VITESCO TECHNOLOGIES GMBHInventors: Giandomenico Serra, Gisella Di Domizio, Ivo Lorenz
-
Publication number: 20210095020Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: ApplicationFiled: May 11, 2020Publication date: April 1, 2021Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAFF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, JR., Haiguang XIAO, Danlin YANG
-
Publication number: 20210040158Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: ApplicationFiled: October 19, 2020Publication date: February 11, 2021Inventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
-
Patent number: 10844095Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: February 4, 2019Date of Patent: November 24, 2020Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
-
Publication number: 20200291135Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.Type: ApplicationFiled: February 25, 2020Publication date: September 17, 2020Applicant: Rgenix, Inc.Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
-
Publication number: 20200157518Abstract: Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.Type: ApplicationFiled: July 2, 2018Publication date: May 21, 2020Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David A. SCHEINBERG, Thomas J. GARDNER, Derek S. TAN, Jonghan LEE, Ivo LORENZ